10980nam 2200565 450 991050298580332120220928121112.0981-16-4047-5(CKB)4100000012025715(MiAaPQ)EBC6724613(Au-PeEL)EBL6724613(OCoLC)1268113376(PPN)258057734(EXLCZ)99410000001202571520220616d2021 uy 0engurcnu||||||||txtrdacontentcrdamediacrrdacarrierGranulomatous diseases in otorhinolaryngology, head and neck /Sanjana Vijay Nemade, Kiran Jaywant ShindeSingapore :Springer,[2021]©20211 online resource (329 pages)981-16-4046-7 Intro -- Preface -- Acknowledgement -- Introduction -- Clinical Features of Granulomatous Diseases -- Diagnosis of Granulomatous Diseases -- Treatment of Granulomatous Diseases -- Contents -- About the Authors -- Part I: Autoimmune Granulomatous Diseases -- 1: Granulomatosis with Polyangiitis-GPA (Wegener's Granulomatosis) -- 1.1 Background -- 1.2 Epidemiology -- 1.3 Etiopathogenesis -- 1.4 Clinical Features -- 1.4.1 Sinonasal Features -- 1.4.2 Oropharyngeal Features -- 1.4.3 Laryngotracheal Involvement -- 1.4.4 Otological Features -- 1.4.4.1 Hearing Loss -- 1.4.4.2 Vertigo or Disequilibrium -- 1.4.4.3 Facial Paralysis -- 1.4.5 Salivary Gland Involvement -- 1.4.6 Other System Involvement -- 1.5 Diagnosis -- 1.5.1 Classification Criteria for GPA -- 1.5.1.1 Histopathology -- 1.5.1.2 Serology -- 1.5.1.3 Endoscopy -- 1.5.1.4 Imaging: -- 1.5.1.5 Pulmonary Function Tests: -- 1.6 Treatment -- 1.6.1 Maintainance of Remission -- 1.7 Essential Features -- References -- 2: Churg-Strauss Syndrome -- 2.1 Background -- 2.2 Epidemiology -- 2.3 Etiopathogenesis -- 2.4 Clinical Features -- 2.5 Diagnosis -- 2.5.1 The Six Criteria -- 2.5.2 Endoscopy -- 2.5.3 The Birmingham Vasculitis Activity Score (BVAS) -- 2.5.4 Blood Cells and Biomarkers -- 2.5.5 Imaging -- 2.5.6 Histopathology -- 2.5.7 Other Tests -- 2.6 Treatment -- 2.6.1 Oral Corticosteroids and Immunosuppressants -- 2.6.2 Supportive Therapy -- 2.7 Essential Features -- References -- 3: Behcet's Disease -- 3.1 Overview -- 3.2 Epidemiology -- 3.3 Etiopathogenesis -- 3.4 Clinical Features -- 3.4.1 Other System Involvement -- 3.5 Diagnosis -- 3.5.1 Histopathology -- 3.5.2 Other Tests -- 3.6 Treatment -- 3.6.1 Pharmacotherapy -- 3.6.2 Surgery -- 3.7 Essential Features -- References -- Part II: Infective Granulomatous Diseases -- 4: Tuberculosis -- 4.1 Background.4.2 Epidemiology -- 4.3 Etiopathogenesis -- 4.3.1 There are Two Major Patterns of Disease with TB -- 4.4 Clinical Features -- 4.4.1 Laryngeal TB -- 4.4.2 TB of Cervical Lymph Nodes -- 4.4.3 Aural TB -- 4.4.4 Nasal TB -- 4.4.5 TB in the Oral Cavity and Oropharynx -- 4.5 Diagnosis -- 4.5.1 Microscopy and Culture -- 4.5.2 Histopathology -- 4.5.3 Imaging -- 4.5.4 The Mantoux Tuberculin Skin Test -- 4.5.5 Serology -- 4.5.6 Molecular Assay -- 4.5.6.1 Nucleic Acid Amplification Tests -- 4.5.7 Latent TB -- 4.5.8 New Cases of Active TB -- 4.5.9 Previously Treated Cases -- 4.5.9.1 The Standard Re-treatment Regimen Consists of -- 4.5.10 Treatment of Drug-Resistant Tuberculosis -- 4.5.10.1 Medication Administration -- 4.5.10.2 Duration of Treatment -- 4.5.10.3 Surgical Management -- 4.5.10.4 Vaccination -- 4.6 Essential Features -- References -- 5: Syphilis -- 5.1 Background -- 5.2 Epidemiology -- 5.3 Etiopathogenesis -- 5.3.1 Primary Syphilis -- 5.3.2 Secondary Syphilis -- 5.3.3 Tertiary Syphilis (Gummatous Syphilis) -- 5.3.4 Congenital Syphilis -- 5.4 Clinical Features -- 5.4.1 Ear Manifestations -- 5.4.2 The Oral Cavity and Oropharyngeal Manifestations -- 5.4.3 The Larynx and Hypopharyngeal Manifestations -- 5.4.4 The Nose and Nasopharyngeal Manifestations -- 5.5 Diagnosis -- 5.5.1 Clinical Diagnosis is Aided by the Following Diagnostic Tests [18] -- 5.5.2 Darkfield Examination -- 5.5.3 Serologic Tests -- 5.5.4 Histopathology -- 5.5.5 Imaging -- 5.6 Treatment -- 5.6.1 Primary, Secondary, and Early Tertiary Disease -- 5.6.1.1 First-Line Treatment -- 5.6.2 Late Tertiary Disease -- 5.6.2.1 First-Line Treatment -- 5.6.2.2 Alternate Treatment -- 5.6.3 Surgical Management -- 5.7 Essential Features -- References -- 6: Leprosy -- 6.1 Background -- 6.2 Epidemiology -- 6.3 Etiopathogenesis.6.4 Clinical Features -- 6.5 ENT Manifestations -- 6.6 Diagnosis -- 6.6.1 Histopathology -- 6.6.2 Serology -- 6.6.3 Molecular Assay -- 6.6.4 Other Tests -- 6.6.5 Interpretation -- 6.6.6 Imaging -- 6.7 Treatment -- 6.7.1 WHO Recommendations for Treatment of Leprosy [14] -- 6.7.2 United States Recommendations for Treatment of Leprosy [14] -- 6.7.2.1 Surgical Management -- 6.8 Essential features -- References -- 7: Actinomycosis -- 7.1 Background -- 7.2 Epidemiology -- 7.3 Etiopathogenesis -- 7.4 Clinical Features -- 7.4.1 Other Features -- 7.5 Diagnosis -- 7.5.1 Cytology -- 7.5.2 Culture -- 7.5.3 Histopathology -- 7.5.4 Imaging -- 7.5.5 Serology -- 7.5.6 Molecular Assay -- 7.6 Treatment -- 7.7 Essential Features -- References -- 8: Rhinoscleroma -- 8.1 Background -- 8.2 Epidemiology -- 8.3 Etiopathogenesis -- 8.4 Clinical Features -- 8.5 Complications -- 8.6 Diagnosis -- 8.6.1 Endoscopy -- 8.6.2 Microscopy and Culture -- 8.6.3 Histopathology -- 8.6.3.1 The Histologic Findings Correspond to the Three Clinical Stages [7, 8] -- 8.6.4 Imaging -- 8.7 Treatment -- 8.7.1 Surgical Management -- 8.8 Essential Features -- References -- 9: Cat Scratch Disease -- 9.1 Background -- 9.2 Epidemiology -- 9.3 Etiopathogenesis -- 9.4 Clinical Features -- 9.5 Diagnosis -- 9.5.1 Imaging -- 9.5.2 Fine Needle Aspiration Cytology -- 9.5.3 Lymph Node Biopsy -- 9.5.4 Serology -- 9.5.5 Molecular Assay -- 9.6 Treatment -- 9.7 Essential Features -- References -- 10: Lyme Disease -- 10.1 Background -- 10.2 Epidemiology -- 10.3 Etiopathogenesis -- 10.4 Clinical Features -- 10.4.1 Stages of Disease -- 10.4.1.1 Early Localized Infection -- 10.4.1.2 Early Disseminated Infection -- Nervous System Involvement (Neuroborreliosis) -- Cardiovascular Involvement -- 10.4.1.3 Late Disseminated Infection -- 10.5 Diagnosis.10.5.1 Microscopy and Culture -- 10.5.2 Histopathology -- 10.5.3 Immunohistochemistry -- 10.5.4 Serology -- 10.5.5 Molecular Assay -- 10.5.6 Imaging -- 10.5.7 Other Tests -- 10.6 Treatment -- 10.7 Essential Features -- References -- 11: Tularemia -- 11.1 Background -- 11.2 Epidemiology -- 11.3 Etiopathogenesis -- 11.4 Clinical Features -- 11.5 Diagnosis -- 11.5.1 Culture -- 11.5.2 Serology -- 11.5.3 Molecular Assay -- 11.5.4 Histopathology -- 11.5.5 Imaging -- 11.6 Treatment -- 11.6.1 First-Line Therapy -- 11.6.2 Second-Line Therapy -- 11.7 Essential Features -- References -- 12: Aspergillosis -- 12.1 Background -- 12.2 Epidemiology -- 12.3 Etiopathogenesis -- 12.4 Risk Factors -- 12.5 Clinical Features -- 12.5.1 Saprophytic Aspergillosis -- 12.5.1.1 Aspergilloma (Fungal Ball) -- 12.5.1.2 Chronic Pulmonary Aspergillosis (CPA) -- 12.5.2 Allergic Aspergillosis -- 12.5.3 Invasive Aspergillosis -- 12.6 Diagnosis -- 12.6.1 Microscopy and Culture -- 12.6.2 Histopathology -- 12.6.3 Immunohistochemistry for Fungal Identification -- 12.6.4 Imaging -- 12.6.5 Serology -- 12.6.6 Molecular Assay -- 12.6.7 Other Tests -- 12.7 Treatment -- 12.7.1 Invasive Aspergillosis (IA) -- 12.7.2 Noninvasive Aspergillosis -- 12.7.3 Glucocorticoids -- 12.7.4 Antifungal Drugs -- 12.7.5 Anti-IgE Therapy -- 12.7.6 Anti-Th2 Therapies -- 12.7.7 Surgical Management -- 12.8 Essential Features -- References -- 13: Mucormycosis -- 13.1 Background -- 13.2 Epidemiology -- 13.3 Etiopathogenesis -- 13.4 Classification -- 13.4.1 Predisposing Factors -- 13.5 Clinical Features -- 13.6 Diagnosis -- 13.6.1 Microscopy and Culture -- 13.6.2 Culture -- 13.6.3 Histopathology -- 13.6.4 Serology -- 13.6.5 Molecular Assay -- 13.6.6 Imaging -- 13.7 Treatment -- 13.7.1 First-Line Monotherapy.13.7.2 Dose of AmB (amphotericin B deoxycholate) -- 13.7.3 Salvage Therapy -- 13.7.4 Surgical Management -- 13.7.5 Post Covid-19 Mucormycosis (From Frying Pan to Fire) -- 13.8 Essential Features -- References -- 14: Rhinosporidiosis -- 14.1 Background -- 14.2 Epidemiology -- 14.3 Etiopathogenesis -- 14.4 Clinical Features -- 14.4.1 Symptoms -- 14.4.2 Signs of Nasal Rhinospridiosis Mass -- 14.5 Diagnosis -- 14.5.1 Cytology and Histopathology -- 14.5.2 Serology -- 14.5.3 Imaging -- 14.6 Treatment -- 14.7 Essential Features -- References -- 15: Candidiasis -- 15.1 Background -- 15.2 Epidemiology -- 15.2.1 Global Emergence of Candida Auris -- 15.2.2 3 Major Concerns About It Are -- 15.3 Etiopathogenesis -- 15.3.1 Virulence Properties of Candida Species -- 15.4 Clinical Features -- 15.4.1 Primary Candidiasis -- 15.4.2 Secondary Candidiasis -- 15.5 Candida-Associated Lesions -- 15.5.1 Denture stomatitis -- 15.6 Diagnosis -- 15.6.1 Microscopy and Culture -- 15.6.2 Histopathology -- 15.6.3 Candida Species Identification -- 15.6.4 Endoscopy -- 15.6.5 Imaging -- 15.6.6 Serology -- 15.6.7 Molecular Assay -- 15.6.8 Blood Tests -- 15.7 Treatment -- 15.8 Essential Features -- References -- 16: Histoplasmosis -- 16.1 Background -- 16.2 Epidemiology -- 16.3 Etiopathogenesis -- 16.4 Clinical Features -- 16.5 Diagnosis -- 16.5.1 Microscopy -- 16.5.2 Culture -- 16.5.3 Histopathology -- 16.5.4 Serology -- 16.5.5 Imaging -- 16.6 Treatment -- 16.7 Essential Features -- References -- 17: Cryptococcosis -- 17.1 Background -- 17.2 Epidemiology -- 17.3 Etiopathogenesis -- 17.4 Clinical Features -- 17.4.1 CNS Manifestations -- 17.4.2 Pulmonary Cryptococcosis -- 17.4.3 Cutaneous and Mucocutaneous Cryptococcosis -- 17.4.4 Other Manifestations -- 17.5 Diagnosis -- 17.5.1 Microscopy and Culture -- 17.5.2 Histopathology.17.5.3 Differentiation Between C. neoformans and C. gattii.GranulomaOtolaryngologyDiagnosisTumorsthubOtorrinolaringologiathubLlibres electrònicsthubGranuloma.OtolaryngologyDiagnosis.TumorsOtorrinolaringologia616.0473Nemade Sanjana Vijay1069144Shinde Kiran JaywantMiAaPQMiAaPQMiAaPQBOOK9910502985803321Granulomatous Diseases in Otorhinolaryngology, Head and Neck2554683UNINA02975nam 2200625 a 450 991097204420332120240514044513.0979-82-16-35582-31-283-30265-997866133026561-61148-009-4(CKB)2550000000057046(EBL)787891(OCoLC)759807479(SSID)ssj0001145484(PQKBManifestationID)12493616(PQKBTitleCode)TC0001145484(PQKBWorkID)11123577(PQKB)10162075(Au-PeEL)EBL787891(CaPaEBR)ebr10504631(CaONFJC)MIL330265(MiAaPQ)EBC787891(EXLCZ)99255000000005704620100401d2010 uy 0engurcn|||||||||txtccrGregory Rabassa's Latin American literature a translator's visible legacy /María Constanza Guzmán1st ed.Lewisburg [Pa.] Bucknell University Press20101 online resource (193 p.)Description based upon print version of record.1-61148-510-X 1-61148-008-6 Includes bibliographical references and index.Why Rabassa?: theorizing the translator's legacy -- Rabassa's conceptions of translation and language -- Del lado de alla y del lado de aca / From this side and from the other: Rabassa's dialogue with his authors -- Ayer y hoy / Past and present: Rabassa's canon and the reception of his translations -- Rabassa's translations and an imagined Latin America.This book takes the case of Gregory Rabassa, translator into English of such canonical novels as Garc'a MOrquez's Cien a-os de soledad and CortOzar's Rayuela. In the chapters, the author historicizes the translator's practice by investigating Rabassa's ideas about translation and his own practice, the relationship between Rabassa and 'his' authors, and the circulation and reception of Rabassa's translations, especially of the works of the so-called Latin American Boom. By critically engaging Rabassa as a translating subject, this book affirms the translator's active role in shaping literary trLatin American literatureTranslations into EnglishHistory and criticismTranslating and interpretingCase studiesTranslating and interpretingPhilosophyLatin American literatureTranslations into EnglishHistory and criticism.Translating and interpretingTranslating and interpretingPhilosophy.428/.0261092Guzmán María Constanza1855694MiAaPQMiAaPQMiAaPQBOOK9910972044203321Gregory Rabassa's Latin American literature4454005UNINA